Aesica Innovation Board
Who we are
The Aesica Innovation Board is comprised of industry experts, both from within Aesica and other respected organisations. They bring together in-depth experience of the whole pharmaceutical supply chain gained from long careers in the pharmaceutical industry.
We established the Aesica Innovation Board to help stimulate pharmaceutical innovation in a climate where developing original technologies and formulations is an ongoing challenge. Our aim is to identify and commercialise modern and novel chemical and pharmaceutical technologies that can add value to our customers, our innovation partners and ourselves, in this ever-competitive marketplace.
By building partnerships with the academic community and with small yet innovative organisations that link with the pharmaceutical industry, we are able to respond to our customers’ appetite for technologies and processes that could help them to:
- Operate more competitively and efficiently
- Overcome technical and processing barriers
- Establish more sustainable manufacturing methods
- Bring their product to market sooner, or extend the lifecycle of their product
What we do
The Aesica Innovation Board looks to identify and connect with like-minded organisations, be they from academia, start-up companies or smaller companies, that are developing technologies with the potential to benefit the wider pharmaceutical industry.
Our successful innovation partners benefit from an investment of resource and experience in order to bring new technologies to market and secure commercial opportunities and practical applications among our established customer base.
With vast experience in contract manufacturing and as a partner to eight of the world’s top ten pharma companies, we help our innovation partners translate their ideas into commercial reality.
What we are looking for
Our mandate is to identify value-adding technologies that enrich pharmaceutical innovation across the entire development lifecycle, from API to formulation development and commercial scale manufacture, including:
- Novel sustainable technologies (such as greener routes to API’s or environmentally packaging)
- New chemical or pharmaceutical technologies
- New engineering solutions
- Innovative drug delivery systems and/or formulations
If you are developing an innovative technology that you would like to propose to the Aesica Innovation Board, contact us for more information – firstname.lastname@example.org
Or to hear how we’re helping our innovation partners at Bradford University to maximise the commercial impact of their technologies, watch this video http://www.outsourcing-pharma.com/Contract-Manufacturing/Aesica-says-academic-partnerships-are-key-for-CMOs/?c=8Q2lu5K88XBRCjC34EHBCRCgC2UAyzQO&utm_source=newsletter_daily&utm_medium=email&utm_campaign=Newsletter%2BDaily
Read our latest published AIB articles:
‘Aesica partners with Durham and Leeds Universities‘ FiercePharma Manufacturing E-Newsletter, December 2012 Edition
‘What’s New?’ Speciality Chemicals Magazine, January 2013 Edition
‘Industry, Academia align in the UK’ Chemical & Engineering News, January 2013 Edition
‘Aesica teams with more academics to optimise Cramlington Plant,’ Outsourcing Pharma Magazine, February 2013 Edition
Global CMO partners with Universities to Commercialise API Manufacturing Technologies European Pharmaceutical Magazine, January/February 2013 Edition